Which Is It, FDA? Now We Know. What the New HHS Compounding Policy Says
If you've been buying vials online labeled "research use only," HHS just pointed to a different path.
Two weeks ago I asked the FDA, which is it? Now there's an answer, and it has strings attached. Here's what the notice says, who it covers, who it leaves out, and what I'd do before spending a dollar.
What HHS Published
The federal health department published a notice in the Federal Register on October 30. It says HHS won't act against state-licensed pharmacies that compound six of these products, as long as each one is made for a single named patient with a prescription. The notice also covers federal facilities and licensed physicians who compound.
That's enforcement discretion. In plain words, HHS is choosing not to act. It is not the FDA signing off on any of these products, and the notice calls the policy non-binding. It says it doesn't create rights for anyone.
The notice is blunt about one more thing. It says FDA doesn't review compounded drugs for safety, effectiveness or quality before they're sold. That's true of all compounding, not just these six.
How We Got Here
In July, a panel of outside advisers to the FDA voted in favor of opening up these six to compounding pharmacies, NPR reported. At the same meeting, the FDA's own scientists recommended against loosening the restrictions. So the experts didn't agree, and HHS went ahead with an interim policy.
How Long It Lasts
It's interim. It runs while the FDA finishes a rule on which bulk ingredients compounding pharmacies may use. FDA may propose adding some or all of the six to that list later, based on the evidence. HHS says it can revise or withdraw the policy if safety or quality problems show up.
The Strings Attached
Condition | What it means for you |
Prescription for one named patient | No stock bottles, no bulk orders |
FDA-registered ingredient maker | Certificate of testing for identity, purity and contaminants |
One active ingredient per product | No blends |
Labeled as compounded, not for resale | You can see what you're getting |
Serious side effects reported | To FDA MedWatch and the state |
Source: Federal Register notice, FR Doc. 2026-22192.
Who Gets Paid Now, and Who Gets Paid Under This
Right now a lot of this money goes to websites selling vials labeled "research use only." NPR calls that the gray market and reports those products are often sourced from overseas suppliers. Nobody named you on the order. Nobody had to show you a test on the ingredient. And there's no pharmacy or prescriber in the loop to report it when something goes wrong.
The path in the policy is different. A prescriber writes it. A state-licensed pharmacy makes it for you by name. The ingredient comes from an FDA-registered maker with a certificate of testing. If there's a serious side effect, it gets reported. Each of those steps costs something, and each one is there for a reason.
Who It Doesn't Cover
Outsourcing facilities, the bigger operations that make higher volumes, aren't covered. Neither are websites selling vials labeled for research use or sold as supplements. The path the policy describes runs through a prescriber and a state-licensed pharmacy.
Don't Expect It Everywhere on Day One
The head of a compounding trade group told NPR it may take time before pharmacies can dispense, because ingredient suppliers have to meet the new standard first, and pharmacies have to check that they did. One compounder told NPR he didn't think every small compounding pharmacy in the country put together could meet the demand. State pharmacy boards aren't bound by the federal policy, either. So this will roll out one pharmacy at a time, if at all in some states.
What I'd Do Before Spending a Dollar
Talk to a prescriber who knows your health history. The policy only works with a prescription for you.
Ask the pharmacy for the certificate of testing on the ingredient. If they can't show it, walk.
Read the label. It should say compounded and name you.
If something feels wrong after a dose, report it to FDA MedWatch.
If you want a say, comments are open on regulations.gov, docket HHS-OASH-2026-0496.
Questions People Ask
Is this the FDA saying these are safe? No. It's a temporary decision not to enforce, with conditions.
Can I keep buying the research vials? The policy doesn't cover those sellers. The route it describes is a prescription filled by a state-licensed pharmacy.
Can I comment? Yes. Comments are open for two weeks after publication, through about November 13.
Then Watch the Price
When something hyped goes cash-pay, the hype tax shows up fast. Done right, you should be paying for the ingredient, the testing and the work of making it. Nobody in between adding their cut. That's how we price everything.
Head to forestparkpharmacy.com to look at our price checker and transfer today to save. See ya.
From Our Shelf
While you're here: Mens Daily Multi, $28.60. Browse more on our shop page.
